All News
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?
An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
Read Article
Does Evusheld shield people living with rheumatic diseases?
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Read Article
In overweight and obese patients with knee OA, 18-months of diet and exercise delivered in community settings significantly reduced WOMAC knee pain (-0.6) compared to an attention control group. Messier S Abs#1675 https://t.co/GvPCGz0NMN #ACR22 @RheumNow https://t.co/yWAwGwunzT
Dr. Antoni Chan synovialjoints ( View Tweet)
Very interesting Thieves Market case... which I have also seen!
Don't forget mycoplasma pneumoniae-induced rash and mucositis (MIRM) when patients presen tw/oral ulceration
My patient had +ANA and carried a dx of PFAPA; only responded to abx!
#ACR22 @RheumNow ABSTR#TMO2 https://t.co/B9dBkZyrlN
Mike Putman EBRheum ( View Tweet)
Walrabenstein et al. RCT of 16-week triple intervention - plant-based diet, exercise, stress management - vs usual care in OA. It works, but we don't know which component, or if Hawthorn effect @RheumNow #ACR22 Abstr#1644 https://t.co/p74Ptd8bZ2 https://t.co/EOg7RxRmO7
Richard Conway RichardPAConway ( View Tweet)
L09 #ACR22 MTX in Post-Roe Era
6% patients reported barrier to MTX access
1 pt noted restriction to HCQ
Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason
Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts
@RheumNow https://t.co/8Yr7nynzN6
Eric Dein ericdeinmd ( View Tweet)
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw
Richard Conway RichardPAConway ( View Tweet)
"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence.
https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W
Links:
Dr. John Cush RheumNow ( View Tweet)
Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU
Richard Conway RichardPAConway ( View Tweet)
Are preexisting autoimmune dx pts okay for
PD-1i/CTLA-4i combo immunoRx
(vs PD-1i single agent)?
Common question in practice for your rheum pts who get cancer
Combo ICI means:
de novo irAE: double risk
flares: same risk
Give our pts what they need!
ABST0757 #ACR22 @RheumNow https://t.co/Vs1AoM54Ut
David Liew drdavidliew ( View Tweet)
Advancing Telemedicine in Rheumatology
'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Stop repeating the #ANA test!
46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
TheDaoIndex KDAO2011 ( View Tweet)
#ACR22 Advancing Telemedicine in Rheumatology
'60% prefer telemedicine for routine visits and review lab results'
https://t.co/HUgoocXodE
@RheumNow #ACR22
Akhil Sood MD AkhilSoodMD ( View Tweet)
Did you know that the first virus, the tobacco mosaic virus, was described in 1892? @AdamJBrownMD gave a fascinating lecture today regarding that included the history of viruses. #ACR22 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Do you know the 3 types of Y. Pestis plague? @AdamJBrownMD reviews the Bubonic, Pneumonic, and Septicemia plagues at #ACR22 @RheumNow. Most recently, there was an outbreak of Pneumonic plague in Madagascar in the 2010s!
Dr. Rachel Tate uptoTate ( View Tweet)
MEFV mutation protected against the plague. Protected against deactivation of inflammasome by yersinia pestis.
@RheumNow #ACR22 #rheuminations https://t.co/OqBay6Svdb
Julian Segan JulianSegan ( View Tweet)
☝️Remember: Not all skin thickening is SSc!
🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN
#ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC
sheila RHEUMarampa ( View Tweet)
🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest
Identifying fetal myocardial targets in congenital heart block (CHB)
Abstract #L13
🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w
Catherine Sims, MD DrCassySims ( View Tweet)
Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD)
- VR naïve & experienced were willing to use VR to manage their RD
- VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD
@RheumNow #ACR22 https://t.co/r7X8Kqp8UN
Akhil Sood MD AkhilSoodMD ( View Tweet)
